Pacritinib was originally developed as a dual inhibitor of FLT3/JAK2 but was recently shown to also robustly and specifically inhibit IRAK1 [41, 42] and has shown some efficacy in treating AML [33, 43]. Here, FLT3 is linked to acute myeloid leukemia.